171 related articles for article (PubMed ID: 37741850)
1. NOXA expression is downregulated in human breast cancer undergoing incomplete pathological response and senescence after neoadjuvant chemotherapy.
Al Shboul S; El-Sadoni M; Alhesa A; Abu Shahin N; Abuquteish D; Abu Al Karsaneh O; Alsharaiah E; Ismail MA; Tyutyunyk-Massey L; Alotaibi MR; Neely V; Harada H; Saleh T
Sci Rep; 2023 Sep; 13(1):15903. PubMed ID: 37741850
[TBL] [Abstract][Full Text] [Related]
2. A three-marker signature identifies senescence in human breast cancer exposed to neoadjuvant chemotherapy.
El-Sadoni M; Shboul SA; Alhesa A; Shahin NA; Alsharaiah E; Ismail MA; Ababneh NA; Alotaibi MR; Azab B; Saleh T
Cancer Chemother Pharmacol; 2023 Apr; 91(4):345-360. PubMed ID: 36964435
[TBL] [Abstract][Full Text] [Related]
3. Expression of therapy-induced senescence markers in breast cancer samples upon incomplete response to neoadjuvant chemotherapy.
Saleh T; Alhesa A; Al-Balas M; Abuelaish O; Mansour A; Awad H; El-Sadoni M; Carpenter VJ; Azab B
Biosci Rep; 2021 May; 41(5):. PubMed ID: 33948615
[TBL] [Abstract][Full Text] [Related]
4. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the expression of P16INK4A by immunohistochemistry in post-neoadjuvant chemotherapy hormone receptor negative breast cancer specimens.
Febres-Aldana CA; Kuritzky N; Krishnamurthy K; Poppiti R; Howard L
Breast Dis; 2020; 39(2):51-59. PubMed ID: 31839602
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.
Nishimura R; Osako T; Okumura Y; Hayashi M; Arima N
Breast Cancer; 2010 Oct; 17(4):269-75. PubMed ID: 19730975
[TBL] [Abstract][Full Text] [Related]
7. Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers.
Enomoto Y; Morimoto T; Nishimukai A; Higuchi T; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Nomura T; Takeda M; Watanabe T; Hirota S; Miyoshi Y
Int J Clin Oncol; 2016 Apr; 21(2):254-261. PubMed ID: 26338270
[TBL] [Abstract][Full Text] [Related]
8. Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer.
Ding Y; Ding K; Qian H; Yu X; Zou D; Yang H; Mo W; He X; Zhang F; Qin C; Zheng Y; Ding X
PLoS One; 2020; 15(4):e0231895. PubMed ID: 32298374
[TBL] [Abstract][Full Text] [Related]
9. High expression of post-treatment Ki-67 status is a risk factor for locoregional recurrence following breast-conserving surgery after neoadjuvant chemotherapy.
Yamazaki N; Wada N; Yamauchi C; Yoneyama K
Eur J Surg Oncol; 2015 May; 41(5):617-24. PubMed ID: 25771264
[TBL] [Abstract][Full Text] [Related]
10. Relationship between the change in tumour-infiltrating lymphocyte level and residual tumour after neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Erol VB; Goktas Aydin S; Bilici A; Cakir A; Acikgoz O; Olmez OF; Basim P
J Chemother; 2023 Nov; 35(7):662-670. PubMed ID: 37599454
[TBL] [Abstract][Full Text] [Related]
11. The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis.
Chen X; He C; Han D; Zhou M; Wang Q; Tian J; Li L; Xu F; Zhou E; Yang K
Future Oncol; 2017 Apr; 13(9):843-857. PubMed ID: 28075166
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
[TBL] [Abstract][Full Text] [Related]
13. Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer.
Alamgeer M; Ganju V; Kumar B; Fox J; Hart S; White M; Harris M; Stuckey J; Prodanovic Z; Schneider-Kolsky ME; Watkins DN
Breast Cancer Res; 2014 Apr; 16(2):R44. PubMed ID: 24762066
[TBL] [Abstract][Full Text] [Related]
14. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
[TBL] [Abstract][Full Text] [Related]
15. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.
Balko JM; Cook RS; Vaught DB; Kuba MG; Miller TW; Bhola NE; Sanders ME; Granja-Ingram NM; Smith JJ; Meszoely IM; Salter J; Dowsett M; Stemke-Hale K; González-Angulo AM; Mills GB; Pinto JA; Gómez HL; Arteaga CL
Nat Med; 2012 Jul; 18(7):1052-9. PubMed ID: 22683778
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.
Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F
Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600
[TBL] [Abstract][Full Text] [Related]
17. Prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer using a deep learning (DL) method.
Qu YH; Zhu HT; Cao K; Li XT; Ye M; Sun YS
Thorac Cancer; 2020 Mar; 11(3):651-658. PubMed ID: 31944571
[TBL] [Abstract][Full Text] [Related]
18. Combination of shear wave elastography and Ki-67 index as a novel predictive modality for the pathological response to neoadjuvant chemotherapy in patients with invasive breast cancer.
Ma Y; Zhang S; Zang L; Li J; Li J; Kang Y; Ren W
Eur J Cancer; 2016 Dec; 69():86-101. PubMed ID: 27821323
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumour cell enumeration does not correlate with Miller-Payne grade in a cohort of breast cancer patients undergoing neoadjuvant chemotherapy.
O'Toole SA; Spillane C; Huang Y; Fitzgerald MC; Ffrench B; Mohamed B; Ward M; Gallagher M; Kelly T; O'Brien C; Ruttle C; Bogdanska A; Martin C; Mullen D; Connolly E; McGarrigle SA; Kennedy J; O'Leary JJ
Breast Cancer Res Treat; 2020 Jun; 181(3):571-580. PubMed ID: 32378053
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
